CD40 and neoplasm: Recent studies suggested that targeting TAMs’ phenotypic reprogramming, using agents like CSF-1R inhibitors [46] or CD40 agonists [47], can boost their antigen-presenting efficiency and activate anti-tumor T-cell responses, offering a novel strategy for HCC immunotherapy.